AACE In the news

March 26, 2024 | The Wall Street Journal

Do You Really Need to Know What Your Blood Sugar Is Doing All Day Long?

People without diabetes will soon be able to track their glucose levels more easily. It isn’t clear whether they should. How closely should you be tracking your blood-sugar levels? AACE President Elect, Scott D. Isaacs, MD, FACP, FACE, provides insights in an article published by The Wall Street Journal.

LEARN MORE

February 28, 2024 | Fox News

Ask a doc: ‘Why am I always thirsty — and what should I do about it?'

If you're always thirsty even though you try your best to drink water and stay hydrated, there may be health-related reasons. AACE Member, Atil Kargi, MD, a clinical endocrinologist in the department of neurosurgery at the University of North Carolina at Chapel Hill, explains the causes in an article published by Fox News Digital.

LEARN MORE

January 23, 2024 | Healthline

Would You Change Jobs to Get Ozempic, Wegovy Coverage? 20% of Americans Say, 'Yes'

The desire for access to anti-obesity medication is so strong that people are more interested in coverage for these medications than other work perks, including child care. AACE Immediate Past President Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE, anticipates that employers may be incentivized to update their health insurance policies depending on how tight the job market is, in an article featured on healthline.com.

LEARN MORE

December 6, 2023 | Health

People Taking Ozempic, Wegovy May See Additional Sleep Apnea Benefits

GLP-1 drugs, like Ozempic and Wegovy, may help people sleep better. AACE President Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE, and AACE member Karl Nadolsky, DO, FACE, DABOM, explain how GLP-1 medications can help with sleep issues, particularly sleep apnea, in an article featured on health.com.

LEARN MORE

November 15, 2023 | Healthline

Black People Are Facing Greater Challenges Accessing Anti-Obesity Drugs Like Ozempic and Wegovy

As the popularity of Ozempic and Wegovy soar for their weight loss benefits, some doctors are concerned about disparities regarding access to these drugs. Fewer Black and Hispanic people are prescribed these medications, yet they are at greater risk for developing type 2 diabetes. AACE President Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE, explains ways to make anti-obesity medications more accessible for everyone, in an article featured on healthline.com.

LEARN MORE

November 3, 2023 | Healthline

Usher Opens Up About His Child's Type 1 Diabetes Journey and How Earlier Detection Can Help

Grammy award-winning singer, songwriter, and dancer, Usher, is speaking out about his child’s journey with type 1 diabetes (T1D), and how early screening can help prepare parents and their children before T1D advances. Rifka C. Schulman-Rosenbaum, MD, chair of the AACE Diabetes Disease State Network, explains the three stages of T1D and the importance for early screening, in an article featured on healthline.com.

LEARN MORE

November 1, 2023 | Healthline

Ozempic and Other GLP-1 Drugs May Contribute to Higher Levels of Social Anxiety

Ozempic and other anti-obesity medications can improve health and aid with significant weight loss. However, with significant weight loss may come anxiety about people’s reactions and views of you. AACE President Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE, shares ways to cope with the newfound attention, in an article featured on healthline.com.

LEARN MORE

October 24, 2023 | Healthline

What to Know Before Taking Obesity Drugs While on Birth Control

GLP-1 receptor drugs, like Mounjaro, may hinder the effectiveness of oral contraceptives. It’s recommended that people taking Mounjaro switch to a non-oral birth control method or add a barrier method of contraception in the timeframe around a dose of the GLP-1 drug. Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and Karl Nadolsky, DO, FACE, DABOM, explain how some forms of contraception may interact with GLP-1 drugs, in an article featured on health.com.

LEARN MORE

October 2, 2023 | Healthline

Ozempic Doesn’t Warn About Mental Health Side Effects, but Wegovy Does

Ozempic does not list anxiety, depression, or suicidal thoughts on its label, yet Wegovy’s label does. The active ingredient in both Ozempic and Wegovy is semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist. AACE President Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE, explains how semaglutide can affect your mental health, in an article featured on healthline.com.

LEARN MORE

October 2, 2023 | Healthline

Managing Type 1 Diabetes Isn’t Rocket Science for This NASA Aerospace Engineer

People with type 1 diabetes are disqualified from flying to space. Rifka Chaya Schulman-Rosenbaum, MD, and Karl Nadolsky, DO, FACE, DABOM, explain how a diagnosis of type 1 diabetes in most cases would not limit career choices, in an article featured on healthline.com.

LEARN MORE

September 27, 2023 | CNN

CNN Exclusive: Prescriptions for Popular Diabetes and Weight-loss Drugs Soared, but Access is Limited for Some Patients

AACE President Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE, shares insights about AACE's development of an obesity algorithm to help stratify the risk of obesity and guide treatment decisions based on a holistic assessment of an individual’s clinical risk factors, in an interview with cnn.com.

LEARN MORE

September 13, 2023 | WUSA9

VERIFY: There is a Shortage of Endocrinologists, but Also of All Doctors

Researchers have been concerned about the number of practicing endocrinologists for at least two decades. AACE President Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE, explains factors that may cause a shortage of endocrinologists and doctors overall, in an article featured on wusa9.com.

LEARN MORE

May 16, 2023 | Good Morning America

Exploring Side Effects of Popular Weight-loss Drugs

AACE President Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE, appeared on Good Morning America about the side effects of the new class of weight-loss drugs that have seen a meteoric rise in popularity and use.

LEARN MORE

April 27, 2023 | CBS Evening News

Eli Lilly Seeks FDA Approval for Weight Loss Drug Tirzepatide

Eli Lilly is requesting fast-track approval from the Food and Drug Administration for its Type 2 diabetes medication tirzepatide to be sold as a weight loss drug. The company said that new studies have shown promising results. AACE Treasurer Scott D. Isaacs, MD, FACP, FACE, spoke on CBS Evening News to provide expert health commentary as a leader in the endocrine field and steward of AACE.

LEARN MORE

April 25, 2023 | Healthline

Are Weight Loss Drugs Like Ozempic Safe While Trying to Get Pregnant?

There currently is not a lot of research on the effects weight loss drugs like Ozempic and Wegovy may have on fertility. AACE President Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE, explains how Ozempic relates to fertility, and how people who are considering conceiving while taking a GLP-1 receptor agonist, should stop taking the medication, in an article featured on healthline.com.

LEARN MORE

April 14, 2023 | Healthline

My Husband and I Both Take Ozempic. Here’s What Our Experience Has Been Like

Married couple Susan and Michael Dixon share how taking Ozempic has affected their health and changed their relationship with food. AACE President Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE, explains the effects of GLP-1 medications, in an article featured on healthline.com.

LEARN MORE

February 27, 2023 | Healthline

My Doctor Prescribed Ozempic to Help Me Lose Weight. Here’s How It’s Going

In 2009 at 38 years old, Joan Lewis underwent chemotherapy to treat breast cancer. From that point on, she began to gain weight. Then her doctor prescribed Ozempic after she was diagnosed with type 2 diabetes. AACE President Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE, explains how Ozempic can improve sugar control in those with type 2 diabetes, and more, in an article featured on healthline.com.

LEARN MORE